Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 27, 2021
Event: Entry into a Material Definitive Agreement (Amended and Restated License and Collaboration Agreement) with Janssen Biotech, Inc.
Key Financial Metrics and Obligations
This filing details a restructuring of development cost obligations rather than reporting standard financial performance metrics (revenue, profit, cash flow) for a specific period.
- Remaining Development Expense Obligation: Approximately $6 million (reduced from previous obligations).
- Previous Obligation Cap: Up to $65 million under the Original Agreement.
- Eliminated Obligations: $25 million for Phase 2 studies of Second Generation Products and $5 million for a potential third Phase 1 study.
- Future Funding Responsibilities:
- PTG-200 Phase 2a: Company funds 20% of costs (subject to $20 million cap).
- PN-235 Phase 1: Company funds 50% of costs incurred through January 4, 2021.
- PN-232 Phase 1: Company funds 100% of agreed-upon costs.
Material Changes Versus Prior Agreement
The Restated Agreement significantly alters the financial and operational scope of the 2017 collaboration with Janssen:
- Expense Reduction: The Company's development cost obligations are limited to specific ongoing studies (PTG-200 Phase 2a, PN-232, and PN-235 Phase 1). Janssen assumes responsibility for all other future development expenses.
- Research Collaboration: The two-year research collaboration has concluded, though Janssen retains rights to conduct additional research through July 2024.
- Milestone Structure: Milestones are no longer strictly indication-specific (e.g., Crohn's disease vs. Ulcerative Colitis) but now correspond to the achievement of milestones in an "initial," "second," or "third" indication, facilitating parallel development.
- Opt-in Payments: Converted into development milestones.
Guidance, Outlook, and Risks
Development Plan: Janssen is required to use commercially reasonable efforts to develop at least one collaboration compound for at least two indications in the IL-23 pathway. The plan contemplates parallel development of multiple compounds.
Commercial Rights: Janssen retains exclusive, worldwide rights to develop and commercialize PTG-200 and second-generation compounds. The Company retains the right to co-detail up to two products in the U.S. market for UC and CD indications.
Risks and Contingencies:
- Forward-looking statements regarding development timelines and expense estimates are subject to risks, including the impact of the COVID-19 pandemic.
- Uncertainty regarding the Company's ability to earn milestone payments.
- Risks related to obtaining and protecting intellectual property rights.
Investor Verification Checklist
- Verify the exact $6 million remaining expense obligation estimate in the upcoming Form 10-Q.
- Confirm the specific clinical trial timelines for PTG-200 (Phase 2a), PN-232, and PN-235 (Phase 1) to assess cash burn rates.
- Review the full text of the Restated Agreement (to be filed as an exhibit to the Q3 2021 10-Q) for detailed royalty tiers and sales milestone triggers.
- Monitor Janssen's progress on the "commercially reasonable efforts" clause to develop compounds for multiple indications.